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Background
Cetuximab, a chimeric mouse-human IgG1 monoclonal
antibody against the epidermal growth factor receptor, is
approved for use in colorectal cancer and squamous-cell
carcinoma of the head and neck. A high prevalence of
hypersensitivity reactions to cetuximab has been reported
in some areas of the United States. IgE antibodies against
cetuximab were present in the patients with cetuximab
hypersensitivity and the antibodies were specific for galac-
tose-1,3-galactose (-gal) in cetuximab heavy-chain. We
have also determined that patients with red meat allergy
have IgE antibodies against ƒ¿-gal in Japan. In 2013, twelve
patients with squamous-cell carcinoma of the head and
neck were treated with cetuximab in Matsue Red Cross
hospital, and found that four of twelve patients had ana-
phylactic shock during first infusion of cetuximab. None
of them had allergic reaction to red meat before the treat-
ment. In this study, we aimed to clarify whether the reac-
tion was IgE-mediated or not.
Method
Serum IgE antibodies against ƒ¿-gal were determined with
CAP-fuorescent enzyme immunoassay (FEIA) (Immuno-
CAP, Phadia) using bovine thyroglobulin (Sigma), and IgE
antibodies against cetuximab (Bristol-Myres Squibb) were
determined with immunoblotting in these patients.
Results
Thyroglubulin-specific IgE was detected in all four patients
with anaphylaxis using CAP-FEIA, whereas the eight
patients who had no anaphylactic reaction had not -gal-
specific IgE antibodies, indicating that sensitivity and
specificity of the thyroglubulin-specific IgE test were both
100%. Anti-IgE antibodies against cetuximab were
detected in sera of the four patients with anaphylaxis and
two of the patients with no anaphylaxis, indicating that
sensitivity of the IgE-immunoblotting was 100% and speci-
ficity of the test was 75%.
Conclusion
CAP-FEIA test with bovine thyroglobulin (-gal) is highly
useful for predicting cetuximab-induced anaphylaxis.
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